Cigna Eyes Biosimilars Competing With 25% Of ‘Specialty’ Products
US Insurer Lauds ‘Societal Opportunity,’ Comments On Potential Margin Profile
Executive Summary
Ahead of adding Humira (adalimumab) biosimilars to its national preferred formulary from 1 February, Cigna spoke about the potential and opportunity of biosimilar competition in the US, which lags behind other OECD member countries.
You may also be interested in...
Eylea Race Continues To Heat Up With Formycon Unveiling Early Positive Data
Weeks after Coherus BioSciences put pen to paper on a deal to bring in Formycon’s FYB203 proposed biosimilar to Eylea (aflibercept), the candidate has shown positive efficacy and safety data, according to preliminary Phase III trial results.
Lannett Eyes Another $11M In Savings With R&D Sea Change, Job Cuts
Lannett unveiled another round of cost-saving initiatives alongside its financial Q2 earnings, including plans for a radical change for its R&D development.
Is There A Biosimilar Future For A Smaller Target Like Synagis?
With something of a revolution in the RSV space on the horizon, Generics Bulletin looks at the potential for biosimilar competition in developed markets to AstraZeneca/SOBI’s existing benchmark option, the 25-year-old prophylactic Synagis (palivizumab).